| PETERKA, Marek, Martin VALIS, Ondrej SOUCEK, Jan KREJSEK, Lukas SOBISEK, Ilona SEJKOROVA, Blanka KLIMOVA, Pavel ŠTOURAČ, Zbysek PAVELEK a Michal NOVOTNY. Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis. EUROPEAN NEUROLOGY. BASEL: KARGER, 2023, roč. 86, č. 5, s. 334-340, 14 s. ISSN 0014-3022. Dostupné z: https://dx.doi.org/10.1159/000532022. |
Další formáty:
BibTeX
LaTeX
RIS
@article{2371617,
author = {Peterka, Marek and Valis, Martin and Soucek, Ondrej and Krejsek, Jan and Sobisek, Lukas and Sejkorova, Ilona and Klimova, Blanka and Štourač, Pavel and Pavelek, Zbysek and Novotny, Michal},
article_location = {BASEL},
article_number = {5},
doi = {http://dx.doi.org/10.1159/000532022},
keywords = {Multiple Sclerosis; Interferon Beta-1a; Glatiramer Acetate},
language = {eng},
issn = {0014-3022},
journal = {EUROPEAN NEUROLOGY},
title = {Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis},
url = {https://karger.com/ene/article/86/5/334/860198/Interferon-Beta-1a-versus-Glatiramer-Acetate},
volume = {86},
year = {2023}
}
TY - JOUR
ID - 2371617
AU - Peterka, Marek - Valis, Martin - Soucek, Ondrej - Krejsek, Jan - Sobisek, Lukas - Sejkorova, Ilona - Klimova, Blanka - Štourač, Pavel - Pavelek, Zbysek - Novotny, Michal
PY - 2023
TI - Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis
JF - EUROPEAN NEUROLOGY
VL - 86
IS - 5
SP - 334-340
EP - 334-340
PB - KARGER
SN - 00143022
KW - Multiple Sclerosis
KW - Interferon Beta-1a
KW - Glatiramer Acetate
UR - https://karger.com/ene/article/86/5/334/860198/Interferon-Beta-1a-versus-Glatiramer-Acetate
N2 - Introduction: Multiple sclerosis is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to the axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. Methods: Sixty Caucasian female patients with relapsing-remitting multiple sclerosis undergo blood sample testing for 15 blood parameters at baseline, 1M, 3M and 6M after treatment by GA or IFN (started as their first line DMD). Results: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. Conclusion: Innate immunity has long been neglected in MS immunopathology. The findings of this study show that innate immunity cells, especially monocytes may contribute significantly to MS immunopathology.
ER -
PETERKA, Marek, Martin VALIS, Ondrej SOUCEK, Jan KREJSEK, Lukas SOBISEK, Ilona SEJKOROVA, Blanka KLIMOVA, Pavel ŠTOURAČ, Zbysek PAVELEK a Michal NOVOTNY. Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis. \textit{EUROPEAN NEUROLOGY}. BASEL: KARGER, 2023, roč.~86, č.~5, s.~334-340, 14 s. ISSN~0014-3022. Dostupné z: https://dx.doi.org/10.1159/000532022.
|
